Given its centrality in AML biology and the promising results of selective ADAR1 inhibition, further exploration of ADAR1-targeted therapies, especially in TP53-mutant and stem-cell–driven AML, may offer a new frontier in overcoming therapeutic resistance and achieving durable remissions. Here, TP53 is linked to acute myeloid leukemia.